{
    "nctId": "NCT03604315",
    "briefTitle": "Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF",
    "officialTitle": "Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 300,
    "primaryOutcomeMeasure": "Poly (ADP-ribose) polymerase inhibitor (PARP)-1 activity as assessed by fluorine F 18 fluorthanatrace positron emission tomography/computed tomography",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* History of known or suspected solid tumor.\n* At least one lesion \u2265 1.0 cm that is seen on standard imaging (e.g. computed tomography \\[CT\\], magnetic resonance imaging \\[MRI\\], ultrasound, fludeoxyglucose \\[FDG\\] PET/CT).\n\nExclusion Criteria:\n\n* Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential \\< 2 weeks prior to screening as standard of care.\n* Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.\n* Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}